EpiVario Inc. With their expertise in epigenetics, they have developed pharmacotherapeutics that target a newly discovered epigenetic process in long-term memory formation. This innovative approach has shown great promise in addressing conditions such as post-traumatic stress disorder (PTSD) and substance use disorders like alcohol, nicotine, and opioid addiction.

Led by renowned neuroepigenetics experts Dr. Shelley Berger and Dr. Philipp Mews, the company is pioneering the development of epigenetic therapeutics to bring relief to patients suffering from these debilitating disorders.

By focusing on reducing the distress associated with trauma memories, EpiVario aims to provide more effective treatments that alleviate the psychological and financial burdens on patients, families, and society. EpiVario’s groundbreaking research has been published in prestigious scientific journals such as Nature, highlighting their expertise and contributions to the field of neuroepigenetics. They have also garnered significant attention and funding, as evidenced by their recent appointment of new scientific advisory board members, expansion of operations, and receipt of an NIH grant.

With an accomplished team of researchers, executives, and advisors, EpiVario is driven by a shared mission to revolutionize therapies for psychiatric disorders and improve the lives of millions worldwide. If you're interested in learning more about EpiVario's work and the technology behind it, don't hesitate to reach out to them. They are ready to make a lasting impact in the field of neuropsychiatric disorders and look forward to hearing from you